Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY25
Investor Presentation
Q2 FY25
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
4
Neutral
2
Bullish
8
Bearish
36
Neutral
2
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Discovery themes featuring this stock
Medicamen Organics Limited specializes in developing, manufacturing, and distributing a diverse range of pharmaceutical products including tablets, capsules, syrups, and dry powders.
The company is strategically focused on global expansion, notably entering the Nepalese market through a partnership with Medi Hub Organic Limited, complemented by a new subsidiary, Grande Etoile Pharmaceuticals.
Medicamen witnessed a substantial 51% increase in revenue year-on-year and a 54% rise in PAT, driven by its strategic initiatives and operational efficiencies.
The company is capitalizing on consumer trends in the global beauty market with its new endeavor into cruelty-free cosmetics and skincare, aiming for a significant share in the $700 billion market.
Medicamen recently issued 4,65,910 convertible warrants on a preferential basis to the Promoter Group to raise INR3 crores, strengthening its working capital for further growth.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
26 Cr
Low Risk
6.0
43.5
0.0
0.9
49.70
19.60
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
6.00 | 37 Cr | -3.23 | 0.83 | 0.00 | -15.00 | -13.49 | -12.63 | |
10.95 | 36 Cr | 7.55 | 0.86 | 0.00 | 8.41 | 12.26 | 4.11 | |
34.56 | 33 Cr | 11.41 | 1.00 | 2.31 | 3.69 | 5.32 | 2.80 | |
41.70 | 32 Cr | -27.15 | 3.66 | 0.00 | -13.06 | 39.56 | -5.20 | |
21.85 | 26 Cr | 5.97 | 0.87 | 0.00 | 14.02 | 13.68 | 7.49 | |
3.13 | 17 Cr | 34.78 | 2.21 | 0.00 | -0.79 | 1.96 | 4.20 |
Medicamen Organics Ltd (MEDIORG) is currently trading at 21.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Medicamen Organics Limited specializes in developing, manufacturing, and distributing a diverse range of pharmaceutical products including tablets, capsules, syrups, and dry powders. The company is strategically focused on global expansion, notably entering the Nepalese market through a partnership with Medi Hub Organic Limited, complemented by a new subsidiary, Grande Etoile Pharmaceuticals. Medicamen witnessed a substantial 51% increase in revenue year-on-year and a 54% rise in PAT, driven by its strategic initiatives and operational efficiencies. The company is capitalizing on consumer trends in the global beauty market with its new endeavor into cruelty-free cosmetics and skincare, aiming for a significant share in the $700 billion market. Medicamen recently issued 4,65,910 convertible warrants on a preferential basis to the Promoter Group to raise INR3 crores, strengthening its working capital for further growth.
Over the past 52 weeks, Medicamen Organics Ltd has traded between a low of ₹19.60 and a high of ₹49.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Medicamen Organics Ltd has a market capitalization of approximately 25.56. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Medicamen Organics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 5.97 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 25.56 Cr, Medicamen Organics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Medicamen Organics Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Medicamen Organics Ltd is 5.97. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
